Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) marks a stem-like colorectal cancer population but is difficult to target directly because of its expression in normal intestinal stem cells. Here, we integrated transcriptomic, somatic mutation, and copy-number data from 396 colorectal tumors to define...
Lucía Paniagua-Herranz, A. Feito, Cristian Privat et al.· bioRxiv· 0 citations
ABBV-CLS-484 is tolerable, with preliminary evidence of clinical activity in dose escalation, and additional strategies that combine ABBV-CLS-484 with VEGF TKIs, CAR-T therapy, and T cell engagers are being tested in preclinical models.
H. Hammers, E. Calvo, B. Carneiro et al.· The Oncologist· 0 citations
Abstract Background SAR443216 is an engineered human trispecific antibody that targets human epidermal growth factor receptor 2 (HER2)-positive (HER2+) cancer cells and activates T cells via co-engagement of cluster of differentiation (CD)3 and CD28. This first-in-human, dose-escalation study evaluated the safety, effi...
E. Dumbrava, Do-Youn Oh, Min-Hee Ryu et al.· Journal for ImmunoTherapy of...· 0 citations
LGR5 expression defines a colorectal cancer subset that is pharmacologically tractable despite the absence of genetic dependency, including condensate-directed modulation of NKD1 as a route to targets inaccessible by antibody- or pocket-based approaches.
Lucía Paniagua-Herranz, A. Feito, Cristian Privat et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.